<DOC>
	<DOC>NCT01402154</DOC>
	<brief_summary>The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.</brief_summary>
	<brief_title>EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>The patient must have given his/her informed and signed consent The patient must be insured or beneficiary of a health insurance plan Histologically proven presence of prostate adenocarcinoma Localized disease on digital rectal examination Cancer without extensions Acceptance of a curative treatment by the patient The patient is participating in another study The patient is in an exclusion period determined by a previous study The patient is under judicial protection, under tutorship or curatorship The patient refuses to sign the consent It is impossible to correctly inform the patient The patient is taking a hormonemodifying treatment Patient taking adrogenic supplements</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>